J. Karnon

Publication List Details

Period

1999 - 2009

Number

21

Co-Authors

Modelling the expected net benefits of interventions to reduce the burden of medication errors (2008)

Karnon, J., McIntosh, A., Dean, J., Bath, P.A., Hutchinson, A., Oakley, A., ...

Objectives: The aim of this study is to estimate the potential costs and benefits of three key interventions (computerized physician order entry [CPOE], additional ward pharmacists and bar coding) to...

A prospective hazard and improvement analytic approach to predicting the effectiveness of medication error interventions (2007)

Karnon, J., McIntosh, A., Dean, J., Bath, P.A., Hutchinson, A., Oakley, J., ...

Medication errors are an important problem for the UK National Health Service (NHS). The aim of this study was to implement a novel quantitative modelling method to predict rates of preventable...

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis (2004)

Karnon, J., Peters, J., Platt, J., Chilcott, J., McGoogan, E., Brewer, N.

Objectives: To update an earlier published report reviewing the effectiveness and cost-effectiveness of liquid-based cytology (LBC). Data sources: Electronic bibliographic databases, relevant...

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis (2004)

Karnon, J., Peters, J., Platt, J., Chilcott, J., McGoogan, E., Brewer, N.

Objectives: To update an earlier published report reviewing the effectiveness and cost-effectiveness of liquid-based cytology (LBC). Data sources: Electronic bibliographic databases, relevant...

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis (2004)

Karnon, J., Peters, J., Platt, J., Chilcott, J., McGoogan, E., Brewer, N.

Objectives: To update an earlier published report reviewing the effectiveness and cost-effectiveness of liquid-based cytology (LBC). Data sources: Electronic bibliographic databases, relevant...

The role of modelling in prioritising and planning clinical trials (2003)

Chilcott, J., Brennan, A., Booth, A., Karnon, J., Tappenden, P.

Objectives: To identify the role of modelling in planning and prioritising trials. The review focuses on modelling methods used in the construction of disease models and on methods for their analysis...

The role of modelling in prioritising and planning clinical trials (2003)

Chilcott, J., Brennan, A., Booth, A., Karnon, J., Tappenden, P.

Objectives: To identify the role of modelling in planning and prioritising trials. The review focuses on modelling methods used in the construction of disease models and on methods for their analysis...

The role of modelling in prioritising and planning clinical trials (2003)

Chilcott, J., Brennan, A., Booth, A., Karnon, J., Tappenden, P.

Objectives: To identify the role of modelling in planning and prioritising trials. The review focuses on modelling methods used in the construction of disease models and on methods for their analysis...

A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer (2003)

Karnon, J., Johnston, S. R. D., Jones, T., Glendenning, A.

Background: Third-generation aromatase inhibitors are being considered as an alternative to tamoxifen as first-line therapy for advanced breast cancer. These newer therapies are more expensive, and...

A model for analyzing the cost of the main clinical events after lung transplantation (2001)

Sharples, L. D., Taylor, G. J., Karnon, J., Caine, N., Buxton, M., McNeil, K., ...

Background: The aim of this project was to model clinically important events experienced by lung transplant patients (from the day after transplant to 5 years or death) and costs associated with...

The effects of neonatal screening for sickle cell disorders on lifetime treatment costs and early deaths avoided: a modelling approach (2000)

Karnon, J, Zeuner, D, Ades, AE, Efimba, W, Brown, J, Yardumian, A

Background.The aim of the study was to calculate the cost to the UK National Health Service of providing treatment services for patients with sickle cell disorders. The rates of differential...

Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis (1999)

Zeuner, D., Ades, A., Karnon, J., Brown, J., Dezateux, C., Anionwu, E.N.

Background Antenatal haemoglobinopathy screening is intended to identify pregnancies that are at risk of an affected fetus. If the mother is identified as a carrier, testing is offered to her...

Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis (1999)

Zeuner, D., Ades, A., Karnon, J., Brown, J., Dezateux, C., Anionwu, E.N.

Background Antenatal haemoglobinopathy screening is intended to identify pregnancies that are at risk of an affected fetus. If the mother is identified as a carrier, testing is offered to her...

Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis (1999)

Zeuner, D., Ades, A., Karnon, J., Brown, J., Dezateux, C., Anionwu, E.N.

Background Antenatal haemoglobinopathy screening is intended to identify pregnancies that are at risk of an affected fetus. If the mother is identified as a carrier, testing is offered to her...

Performance, treatment pathways, and effects of alternative policy options for screening for developmental dysplasia of the hip in the United Kingdom

Dezateux, C, Brown, J, Arthur, R, Karnon, J, Parnaby, A

Aims: To compare, using a decision model, performance, treatment pathways and effects of different newborn screening strategies for developmental hip dysplasia with no screening.

Efficiency of alternative policy options for screening for developmental dysplasia of the hip in the United Kingdom

Brown, J, Dezateux, C, Karnon, J, Parnaby, A, Arthur, R

Aims: To assess, using a decision model, the efficiency of ultrasound based and clinical screening strategies for developmental dysplasia of the hip.

Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis

Karnon, J, Kerr, G R, Jack, W, Papo, N L, Cameron, D A

Cost pressures and the need to demonstrate cost-effectiveness of new interventions require consideration of the costs of treating disease. This study presents analyses of resource use data covering...